Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT

This trial studies whether interferon-alpha, a type of immune-stimulating drug, can help prevent relapse in people with blood cancers (myelodysplastic syndrome or acute myeloid leukemia) that have a TP53 gene mutation after they have received a bone marrow transplant from a donor. TP53 mutations are associated with higher relapse risk, and this study aims to use interferon to keep the cancer from coming back. **You may be eligible if...** - You are 12 to 65 years old - You have been diagnosed with MDS or AML with a TP53 mutation - You have recently received your first allogeneic (donor) stem cell/bone marrow transplant - Your MRD (minimal residual disease) testing was negative within 2 months after transplant - Your general health (Karnofsky score) and organ function are adequate - You have no history of severe graft-versus-host disease (GVHD) **You may NOT be eligible if...** - You have severe heart, kidney, or liver disease - You have another active cancer requiring treatment - You have a serious mental illness that prevents you from following the study protocol - You have a life-threatening infection - You are enrolled in another clinical trial Talk to your doctor to see if this trial is right for you.